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An association between schizophrenia and subsequent breast cancer has been suggested;
however the risk of schizophrenia following a breast cancer is unknown. Moreover, the
driving forces of the link are largely unclear. Here, we report the phenotypic and genetic
positive associations of schizophrenia with breast cancer and vice versa, based on a Swedish
population-based cohort and GWAS data from international consortia. We observe a genetic
correlation of 0.14 (95% CI 0.09–0.19) and identify a shared locus at 19p13 (GATAD2A)
associated with risks of breast cancer and schizophrenia. The epidemiological bidirectional
association between breast cancer and schizophrenia may partly be explained by the genetic
overlap between the two phenotypes and, hence, shared biological mechanisms.
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Breast cancer is the most commonly diagnosed canceramong women worldwide1. Some evidence suggests thatvulnerability to stress2–4, particularly indicated by the
presence of psychiatric disorders including schizophrenia5,6, may
be associated with increased risk of subsequent breast cancer.
Conversely, recent studies by us and others support that patients
with breast cancer are at higher risk of a range of psychiatric
disorders subsequently, including depression, anxiety, and post-
traumatic stress disorder7,8. The longitudinal bidirectional asso-
ciation raises the question of shared risk factors between breast
cancer and psychiatric disorders.
A hypothesized link between schizophrenia and breast cancer
dates several decades back9. Affecting up to 1% of the population,
schizophrenia is one of the most severe and costliest psychiatric
disorders10. Several risk factors for breast cancer are commonly
present in schizophrenia, including behavioral risk factors such as
smoking, alcohol use, excess bodyweight, and physical inactiv-
ity11–16, as well as prenatal- and early-life exposure to stress17,18.
Despite lower attendance to mammography screening in patients
with schizophrenia19, the results from a recent meta-analysis
suggest that schizophrenia is associated with increased risk of
breast cancer6. Meanwhile, the subsequent risk of schizophrenia
among breast cancer patients remains unclear. If confirmed, such
longitudinal bidirectional association would lend further support
to the shared risk factors between both diseases rather than one
causing the other. Although recent studies suggest that genetic
markers of schizophrenia are associated with higher risk of breast
cancer20,21, a potential genetic overlap between the diseases has
not been thoroughly assessed.
Here we illustrate the longitudinal association of schizophrenia
with subsequent risk of breast cancer and vice versa, by utilizing a
Swedish population-based cohort. Leveraging data from inter-
national consortia, we further find evidence for a shared genetic
basis between breast cancer and schizophrenia and identify a
shared locus. Together with the pathways enriched in the func-
tional annotation, our findings may shed light on the potential
biological mechanisms that drive the susceptibility to both
diseases.
Results
Longitudinal phenotypic association between two diseases.
Using nationwide population and health registers in Sweden, we
identified all women with invasive breast cancer (N= 94,626)
diagnosed in Sweden during 1990–2009 (mean age at diagnosis,
63.6 ± 14.1 years). For each cancer case, at the time of cancer
diagnosis, we randomly selected 30 cancer-free women as con-
trols (N= 2,838,765) who were individually matched on birth
year. By cross-linkage to the Patient Register, we identified any
first-ever inpatient or outpatient diagnoses of schizophrenia
before or after the date of cancer diagnosis for cases and matching
date for controls.
First, we examined the association of schizophrenia with
subsequent invasive breast cancer. Five hundred and thirty-four
(0.56%) and 11,036 (0.39%) inpatient diagnoses of schizophrenia
were observed among women who later did vs. did not develop
breast cancer, respectively. The nested case–control analysis (i.e.,
assessing the incidence of schizophrenia before the cancer
diagnosis/matching date), by design, is equivalent to the
prospective analysis using full cohort22. Schizophrenia was
associated with a 49% increased risk of subsequent invasive
breast cancer (95% confidence interval [CI], 37–63%, P= 1.72 ×
10−19; Table 1). The association remained robust when including
outpatient diagnoses of schizophrenia and/or additionally con-
trolling for characteristics shared between breast cancer and
schizophrenia, such as parity, and previous diagnoses of
psychiatric disorders (including substance use disorders) and
obesity (Table 1).
Second, we assessed the risk of schizophrenia following
invasive breast cancer in a matched cohort analysis (i.e.,
addressing incidence of schizophrenia after the cancer diagno-
sis/matching date). We excluded women with inpatient or
outpatient diagnosis of schizophrenia prior to the matching
(N= 11,947). During the follow-up (from the matching up to
December 31, 2010), we noted 100 (0.11%) and 2584 (0.09%)
first-ever inpatient diagnoses of schizophrenia among women
with and without breast cancer, respectively. We found that
women with invasive breast cancer were at 31% increased risk
of hospitalization for schizophrenia (95% CI, 7–61%, P= 0.008).
An increased risk was also indicated when we included outpatient
visits for schizophrenia and/or additionally controlling for
parity and previous diagnoses of psychiatric disorders and
obesity (Table 1).
To shed light on the early-onset schizophrenia, we restricted
the analysis to women aged 18–44 years and suggested a
bidirectional, positive association between early-onset schizo-
phrenia and breast cancer, although the numbers were small and
estimates were not statistically significant (Supplementary
Table 1).
These results confirm a longitudinal, bidirectional association
between breast cancer and schizophrenia, which is not entirely
explained by proxies of major environmental risk factors shared
by both traits. Although unmeasured confounders cannot be
ruled out, one possible explanation is the common genetic factors
underlying both traits.
Genetic overlap between breast cancer and schizophrenia.
Given the observation in the epidemiological analysis, we sub-
sequently focused on confirming and identifying genetic overlap
between schizophrenia and breast cancer in the genetic analysis.
First, we calculated the genetic correlation between breast cancer
and schizophrenia using linkage disequilibrium (LD) score
regression. Genetic correlation is the proportion of variance that
two traits share due to common genetic factors, as an estimate of
the degree of pleiotropy or genetic overlap.
Using summary statistics for breast cancer23 (122,977 cases and
105,974 controls) and schizophrenia24 (33,640 cases and 43,456
controls) from the consortia’s meta-analyzed genome-wide
association studies (GWASs) in populations of European
ancestry, we estimated the genetic correlation between both traits
at 0.14 (95% CI, 0.09–0.19, P= 5.30 × 10−8), suggesting that
around one-seventh of the genetic contribution to these two
phenotypes is shared. A significant, albeit small, LD score
regression intercept (0.03, 95% CI 0.01–0.04) suggests a minor
sample overlap between both consortia, which is largely
inevitable.
Based on the same GWAS summary statistics, we next
calculated polygenic risk scores (PRSs) to further assess the
genetic association between breast cancer and schizophrenia.
Single-nucleotide polymorphisms (SNPs) in the extended major
histocompatibility complex (MHC) region (chr6: 25–34Mb) were
removed due to the long-range LD and unusual genetic
architecture. The PRS for schizophrenia was significantly
associated with the risk of breast cancer and vice versa across
most P value thresholds (PTs; Fig. 1). The association became
more significant along with increasing threshold. At PT < 0.4712
(i.e., PRS was computed using all SNPs below the threshold after
LD clumping), the association between PRS for schizophrenia
and breast cancer yielded the lowest P value (odds ratio [OR]
1.023, 95% CI 1.022–1.025, P= 3.57 × 10−186), explaining 0.37%
of the variance. At PT < 0.4492, the association between PRS for
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breast cancer and schizophrenia yielded the lowest P value (OR
1.070, 95% CI 1.065–1.075, P= 3.16 × 10−177), explaining 1.04%
of the variance. Notably, the association between the breast
cancer PRS and schizophrenia appears when large numbers
of SNPs weakly associated with breast cancer are included in
the analysis, in support of the polygenic architecture in
schizophrenia.
Circulating sex hormones are well-confirmed predictors of
breast cancer risk25, whereas sex hormones may possibly play a
role in schizophrenia development, particularly the differential
risk between women and men26. To address potential differences
in the genetic overlap between different subgroups of breast
cancer and schizophrenia, we performed separate analyses among
estrogen receptor (ER)-positive and ER-negative breast cancer as
well as female and male schizophrenia. Using the GWAS
summary statistics from consortia, similar findings were noted
in the associations between schizophrenia and both ER-positive
and ER-negative breast cancer (Supplementary Fig. 1). As the





N (%) N (%) OR (95% CI)a Pa OR (95% CI)b Pa
Association of schizophrenia with subsequent breast cancerc
Number of women 2,838,765 94,626 — — — —
Clinical diagnosis of schizophrenia
Inpatient diagnosis 11,036 (0.39) 534 (0.56) 1.49 (1.37–1.63) 1.72 × 10−19 1.40 (1.28–1.53) 4.28 × 10−14
Inpatient or outpatient
diagnosis
11,399 (0.40) 548 (0.58) 1.48 (1.36–1.62) 2.54 × 10−19 1.39 (1.28–1.52) 1.17 × 10−14
N (%) N (%) HR (95% CI)a Pa HR (95% CI)b Pa
Association of breast cancer with subsequent schizophreniad
Number of women 2,827,366 94,078 — — — —
Clinical diagnosis of schizophrenia
Inpatient diagnosis 2584 (0.09) 100 (0.11) 1.31 (1.07–1.61) 0.008 1.29 (1.03–1.62) 0.029
Inpatient or outpatient
diagnosis
3728 (0.13) 135 (0.14) 1.23 (1.03–1.46) 0.019 1.13 (0.93–1.37) 0.218
N number, OR odds ratio, HR hazard ratio.
aModels were adjusted for educational level (primary school, high school, college and beyond, or unknown) and region of residence (southern, central, or northern Sweden). Birth year and age at
reference were inherently controlled for due to matching.
bModels were additionally adjusted for parity (0, 1–2, or ≥3), pre-existing psychiatric disorder (yes or no; including substance use disorders), and obesity (yes or no) at matching.
cBased on the nested case–control study. The estimates, i.e., OR derived from conditional logistic regression, should be interchangeably interpreted as the risk of breast cancer among patients with
schizophrenia.






































































































































































































Fig. 1 Genetic association between breast cancer and schizophrenia based on GWAS summary statistics of breast cancer and schizophrenia. a PRS for
schizophrenia associated with risk of breast cancer. b PRS for breast cancer associated with risk of schizophrenia. We performed PRS analysis based on
GWAS summary statistics. We plotted the variance of one disease (Y axis) explained by the genetic markers associated with the other disease under a P
value threshold (X axis). The number above the bar indicates the statistical significance of the genetic association (two-sided P value). GWAS genome-
wide association study, PRS polygenic risk score.
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GWAS summary statistics are not publicly available for
schizophrenia by sex, we then used individual-level genotype
data from the Swedish Schizophrenia Study [S3] for such analysis
(in total 4924 cases of schizophrenia and 6207 controls). Despite
less significant associations compared with the results found
using consortia data, similar magnitudes in effect sizes (i.e., ORs)
of PRS for breast cancer were noted between female and male
schizophrenia (Supplementary Table 2).
A distinct signal shared by breast cancer and schizophrenia. To
identify the strongest genetic loci shared between breast cancer
and schizophrenia, we first visualized the associations of lead
SNPs (i.e., genome-wide significant SNPs after LD clumping) for
schizophrenia with the risk of breast cancer, and vice versa. When
assessing 91 genome-wide significant SNPs for schizophrenia, we
approximated the average effects of these alleles on breast cancer
and observed a positive association (P= 6.07 × 10−6; Fig. 2).
When focusing on the 140 lead SNPs for breast cancer, we
observed no overall correlation with schizophrenia (P= 0.425).
After correcting for multiple testing, six lead SNPs of schizo-
phrenia were significantly associated with breast cancer, while
nine lead SNPs of breast cancer were also associated with
schizophrenia.
Considering the significant heterogeneity in the tests of
association, we further visualized the associations by filtering all
influential points out (according to Cook’s distance) and by
removing SNPs iteratively until the heterogeneity test was no
longer significant. The results remained largely similar. The
association between lead SNPs for schizophrenia and risk of
breast cancer was significant (P= 0.024), although somewhat
attenuated (Supplementary Fig. 2).
The 15 lead SNPs come from 14 loci, which we examined
individually by using regional association plots to assess
colocalization of the signals (i.e., if the top variants for the 2
traits are highly correlated). We identified a common locus at
19p13 anchored by the lead SNPs rs2965183 and rs2905426 (LD
r2= 0.93) for breast cancer and schizophrenia, respectively (Fig. 3
for locus 19p13 and Supplementary Fig. 3 for other loci). The
variants at 19p13 was positively associated with increased risks of
both breast cancer and schizophrenia (e.g., rs2965183: effect
size= 0.04, P= 8.40 × 10−12 for breast cancer; effect size= 0.07,
P= 4.07 × 10−9 for schizophrenia). Based on PhenoScanner
database27, this locus is also associated with lipid levels (including
total cholesterol (TC), triglycerides (TG), and low-density
lipoprotein [LDL]). However, the associations with lipid levels
are in the opposite direction as seen for breast cancer and
schizophrenia (Supplementary Table 3). Moreover, we plotted
regional associations of locus 19p13 with lipid levels. The patterns
were distinctly different from breast cancer or schizophrenia, as
the strongest markers of lipid levels are of low/limited correla-
tions with rs2965183/rs2905426 (r2 < 0.16; Supplementary Fig. 4).
Thus the signal at 19p13 shared by breast cancer and
schizophrenia is unlikely explained by the genetic susceptibility
to aberrant levels of lipids. We further searched other reported
associations in this region using GWAS Catalog28 and found 49
associations with 32 phenotypes (broadly categorized into lipids,
blood count, psychobehavioral profiles, and others) in addition to
breast cancer and schizophrenia (Supplementary Table 4).
However, these associations, except for basophil count and red
blood cell distribution width (r2 from 0.813 to 0.871), are less
correlated with rs2965183/rs2905426 (r2 < 0.6). This suggests
that the signal at 19p13 shared by breast cancer and schizo-
phrenia is less likely explained by the genetic susceptibility to the
aforementioned traits.
Next, we performed the cis-expression quantitative trait locus
(eQTL) analysis of these two SNPs (rs2965183 and rs2905426) for
genes up to 1Mb on either side of each variant. We used gene
expression data from tissues of breast (N= 251), brain (N= 80–154,
depending on brain regions), or blood samples (N= 369) in the
Genotype-Tissue Expression (GTEx) Project29. In blood samples,
the risk alleles (A) of rs2965183 and (G) of rs2905426 were
associated with elevated expression of nearby genes GATAD2A
(corrected P= 3.34 × 10−15) and TSSK6 (corrected P= 4.15 × 10−5)
but reduced expression of LPAR2 (corrected P= 1.83 × 10−18) and
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Fig. 2 Associations of lead SNPs for schizophrenia with the risk of breast cancer, and vice versa. a Lead SNPs for schizophrenia associated with breast
cancer (n= 122,977 breast cancer cases and 105,974 controls). b Lead SNPs for breast cancer associated with schizophrenia (n= 36,989 schizophrenia
cases and 113,075 controls). We plotted the associations of genetic markers for one disease (the effect size shown as X axis) with the other disease (Y
axis) based on GWAS summary statistics. Data are presented as OR (dots) and 95% confidence interval (error bars). Orange dots denote variants of P <
0.05 after false discovery rate (FDR) adjustment. We then derived the average effect of the set of genetic markers on the other disease using a global test.
The dash line indicates this effect size, while the full statistical results were reported below the plot. P values are two sided. N number, OR odds ratio; Phet,
P for heterogeneity, SD standard deviation, SE standard error, SNP single-nucleotide polymorphism.
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variants were associated with increased level of TM6SF2 in brain
tissues (corrected P values <0.01). Moreover, the variants of
rs2965183 and rs2905426 were related to higher expression of
HAPLN4 in breast (corrected P= 0.001) and brain tissues (corrected
P= 1.9 × 10−4), respectively. All the aforementioned genes were
nearby locus 19p13.
Potential pathways shared by breast cancer and schizophrenia.
As evidenced by the PRS analysis and the significant genetic
correlation between schizophrenia and breast cancer, it is unlikely
that the association is only driven by the signal at 19p13. We,
therefore, performed a pathway analysis to identify more com-
mon mechanisms. We first mapped the overall genetic archi-
tecture shared by breast cancer and schizophrenia using cross-
trait meta-analysis with adjustment for overlapping controls. To
avoid detecting signals unduly driven by association from one
side, we restricted the analysis to 946 SNPs of P < 5 × 10−5, of
which 897 SNPs (94.8%) were with effect sizes in the same
direction for both traits. These SNPs came from 17 genomic loci
(Supplementary Fig. 5) and were mapped to 84 genes confirmed
by either position mapping or eQTL analyses using breast, brain,
or blood samples from GTEx. Utilizing databases including Gene
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Fig. 3 Regional association plot of GWAS summary statistics from breast cancer and schizophrenia for the locus 19p13. a Associations with breast
cancer. b Associations with schizophrenia. SNPs are colored corresponding to which of the lead SNPs it is in highest LD with, and the gradient of color
denotes the extent of LD (i.e., lighter color means lower LD). This locus is anchored by lead SNPs rs2965183 (magenta) and rs2905426 (turquoise) for
breast cancer and schizophrenia, respectively. GWAS genome-wide association study, LD linkage disequilibrium, SNP single-nucleotide polymorphisms.
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Kyoto Encyclopedia of Genes and Genomes (KEGG), we detected
an enrichment of 176 pathways (all with P < 0.05 after correction
of multiple comparison separately in each database, Supplemen-
tary Data 1). The most significantly enriched pathway regulates
the biosynthesis of peptide hormones (e.g., corticotropin) that
mediate neurotransmission and hormonal action (corrected P=
1.57 × 10−5).
Discussion
To the best of our knowledge, this is the first in-depth dissection,
from phenotypic to genetic associations, of the link between
breast cancer and schizophrenia. Leveraging the Swedish
nationwide population-based cohort, we showed an epidemiolo-
gical bidirectional association between breast cancer and schizo-
phrenia. Consistently, we further illustrated the genetic
association of both traits using GWAS summary statistics from
international consortia and identified a distinct locus (19p13)
shared between breast cancer and schizophrenia using regional
association plots. The noteworthy genetic overlap between breast
cancer and schizophrenia may partly explain the phenotypic
association found in the epidemiological analysis, and the iden-
tified shared locus may provide leads to the potential common
biology for both traits.
Despite lower screening attendance19, it has recently been
recognized that patients with schizophrenia are at increased risk
of breast cancer6 but not of cancer overall30,31. Our results
demonstrate that women with breast cancer are also at elevated
risk of subsequent schizophrenia—largely representing a late-
onset group documented as the second incidence peak following
menopause26. It is plausible that many patients with schizo-
phrenia who developed breast cancer later were early-onset ones,
which might be phenotypically different from those developed
after breast cancer. Our additional analysis restricting to women
aged 18–44 years lends some support to a bidirectional associa-
tion between early-onset schizophrenia and breast cancer,
although the statistical power was very limited. The longitudinally
bidirectional association in epidemiological analysis may point
toward a partially shared etiology. Common behavioral or life-
style factors (including nulliparity and obesity) have previously
been suggested6, but our results remained robust in an effort to
control for these factors. It is also hypothesized that some treat-
ment for schizophrenia, for instance, antipsychotics, may induce
higher level of prolactin and subsequently increased risk of breast
cancer6. Nevertheless, use of antipsychotics may not explain the
excess risk of schizophrenia among patients with breast cancer.
Altogether, these evidences lend some support to a potential
genetic overlap between both diseases.
A recent study reporting shared genetic variants between
schizophrenia and lung cancer highlighted a locus related to
nicotinic acetylcholine receptors and smoking32. In the same
study, based on a much smaller GWAS consortium of breast
cancer (the Genetic Associations and Mechanisms in Oncology
consortium (GAME-ON)), a weaker association between schi-
zophrenia and breast cancer was detected by the stratified
quantile–quantile plot and no further analysis was pursued32.
Recently, both Byrne et al.20 and Shi et al.21 performed Mendelian
randomization analyses based on similar GWAS summary sta-
tistics, which indicate that the genetic determinants of schizo-
phrenia are associated with an increased risk of breast cancer.
Another study based on GAME-ON data does, however, not
support a causal genetic correlation between the two diseases33.
Together with the longitudinal, bidirectional association observed
in the epidemiological analysis and the weak pattern in the scatter
plot of the lead SNPs, our findings also suggest a genetic overlap
between the two traits rather than that one causing the other. We
estimated that around one-seventh of the genetic contribution to
breast cancer is shared with genetic contribution to schizo-
phrenia, which is in line with previous reports20,34. In fact, the
genetic correlation of 0.14 between schizophrenia and breast
cancer (as a somatic disease) is noteworthy in comparison with
genetic correlation between some psychiatric disorders, for
example, between schizophrenia and autism (rg= 0.14)35. Of
note, the genetic overlap is also noted between breast cancer and
other psychiatric traits including depressive symptoms and neu-
roticism34. By contrast, some non-significant genetic correlations
were detected between schizophrenia and other cancer types (e.g.,
ovarian cancer) but no correlation with colorectal cancer34.
The novelty of our study further lies in the discovery of a
distinct signal at 19p13 that is associated with both breast cancer
and schizophrenia. A careful search of previously reported asso-
ciations in this region support that this shared locus is not clearly
explained by other traits. Importantly, this locus has also been
identified as a shared locus associated with three hormone-related
cancers, including breast, ovarian (P= 0.0063), and prostate
cancer (P= 0.01)36, although a precise biological pathway cannot
be pinpointed by these data. The index cross-cancer variant
rs1469713 is located between the lead SNPs of breast cancer
(rs2965183, 16 kb downstream) and schizophrenia (rs2905426,
50 kb upstream). rs2965183 is located in enhancer elements
reported to interact with GATAD2A in normal and tumor breast
cells36. Our results also show that the locus 19p13 is associated
with increased expression of GATAD2A in blood samples, while
others observed a similar pattern in brain tissue37,38. GATAD2A
is a subunit of the nucleosome remodeling and histone deacety-
lase (NuRD) complex. As a chromatin-level regulator of tran-
scription, the NuRD complex may facilitate breast cancer
development and progression by interacting with YAP/TAZ from
the Hippo tumor-suppressor pathway39, modulating estrogen
functions and the human epidermal growth factor receptor 2
pathway40, and by blocking p53-induced apoptosis40. Moreover,
the locus 19p13 is associated with intellectual performance among
broad psychosis cases38. GATAD2A is related to greater pre-
frontal activity41, while NuRD complex regulates gene expression
with temporal precision42. The results of several studies indicate
that GATAD2A may be one of the causal genes in the patho-
genesis of schizophrenia, potentially through dopamine receptor
D2 and nerve growth factor (NGF) pathways41,43,44. NGF sig-
naling was also enriched in our pathway analysis.
As indicated by the PRS analysis and cross-trait meta-analysis,
other weakly associated variants besides the signal at 19p13 may
also pillar the shared genetic architectures between breast cancer
and schizophrenia. In the pathway analysis accounting for weaker
signals, we identified several pathways that are potentially
underlying the two traits. The most significant one is the peptide
hormone biosynthesis pathway (corrected P= 1.57 × 10−5),
which regulates the processing of corticotropin (known as adre-
nocorticotropic hormone (ACTH)), a well-known player in
hypothalamic–pituitary–adrenal axis and hence the stress
response. ACTH and other stress hormones are closely related to
many mental disorders, including schizophrenia45,46, and have a
pivotal role in cancer development, potentially interacting
through immune system and sex hormones47,48. The genetic
association between schizophrenia and ER-positive breast cancer
indeed appeared slightly stronger in our data, although it could be
partially explained by the larger sample size of ER-positive breast
cancer.
One major strength of the present study is the use of large-scale
population data, with high validity data on the diagnoses of
breast cancer and schizophrenia49,50, and genetic data from
multiple sources, to illustrate the consistent association of breast
cancer with schizophrenia risk and vice versa. Nevertheless, we
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acknowledge several limitations. Despite the efforts of addressing
behavior-related factors (e.g., smoking-related comorbidities and
obesity by using proxies of clinically diagnosed tobacco use dis-
order and obesity, respectively), the residual confounding cannot
be ruled out. For instance, we have no information whether the
obesity was pre- or post-menopausal. However, many individuals
had first episode of schizophrenia in their 20s/30s and were
subsequently at risk for overweight/obesity due to antipsychotic
treatment51,52 yielding decreased risk of breast cancer53, which
suggests that our estimates are rather conservative. We also lack
information on hormone levels, e.g., estradiol. However, women
with schizophrenia often have a lower level of circulating estra-
diol54, which would have led to decreased risk of breast
cancer55,56. Moreover, some treatments for schizophrenia (e.g.,
antipsychotics) may induce higher levels of prolactin and thereby
increasing the risk of breast cancer6, whereas breast cancer
treatment (e.g., hormone therapy57 and chemotherapy58) may
effect on brain functions. It is plausible that genetic overlap,
together with potential behavioral factors and treatment, con-
tribute to the observed phenotypic association between breast
cancer and schizophrenia. Replication of the PRS analysis in
individually genotyped studies independent of these two inter-
national consortia would have been preferable. Nevertheless, the
genetic association between breast cancer and schizophrenia has
been observed in several studies using different data sources32,33.
In addition, although we showed that the locus 19p13 shared by
breast cancer and schizophrenia is independent of a number of
traits including blood lipid levels, an association of this locus with
ovarian and prostate cancer has also been suggested36. Thus
future studies are needed to understand the potential genetic
overlap between schizophrenia and other hormone-related can-
cers as well as the link between schizophrenia and male breast
cancer.
In conclusion, our findings suggest that breast cancer and
schizophrenia are both phenotypically and genetically correlated.
The noteworthy genetic contribution to both traits, highlighted by
a shared locus at 19p13 and among other loci, has the potential to
shed light on the common biology underlying breast cancer and
schizophrenia. Functional studies are needed to uncover how the
identified genetic signals contribute to the pathogenesis of both
diseases.
Methods
Data sources. Based on the Swedish Population and Housing Census in 1990, we
identified all women born and living in Sweden in 1990 (N= 3,937,114). Using the
unique national identification numbers, we followed all women through cross-
linkages to the Swedish Cancer Register and Patient Register to identify occurring
cases of breast cancer and schizophrenia, respectively. The Cancer Register has
been available since 1958 and approaches 100% completeness. The Patient Register
has information on ≥80% of hospital discharge records since 1980s, complete
records since 1987, and ≥80% of hospital-based outpatient visits since 2001. The
Cause of Death and Migration Registers were also cross-linked for follow-up.
Demographic characteristics were obtained from the Census. Information on
educational level was retrieved from the Education Register, while parity at
matching was obtained from the Medical Birth Register and the Total Population
Register. In addition, diagnoses of other psychiatric disorders and obesity were
identified from the Patient Register. See Supplementary Table 6 for all diagnostic
codes that were used.
The multi-stage GWAS of breast cancer was recently conducted among 122,977
cases and 105,974 controls of women of European ancestry from 68 studies
collected by the Breast Cancer Association Consortium and Discovery, Biology and
Risk of Inherited Variants in Breast Cancer Consortium23. In each of the
participating studies, genotype data were imputed using the 1000 Genomes Project
reference panel (1KG; Phase 3) and filtered for a minor allele frequency (MAF) ≥
0.5% and imputation quality score ≥0.3, retaining 11.8 million variants. Association
testing was conducted on these imputed markers with adjustment for countries and
ancestry-informative principle components (PCs). A fixed-effect meta-analysis was
conducted combining each result and results from the Collaborative Oncological
Gene–environment Study and other 11 independent GWASs of breast cancer.
The multi-stage GWAS of schizophrenia were performed on up to 36,989 cases
and 113,075 controls by the Schizophrenia Working Group of the Psychiatric
Genomics Consortium (PGC)24. We used the summary statistics from 33,640 cases
and 43,456 controls of European ancestry from 46 ancestry matched, non-
overlapping case–control samples and 3 family-based samples (public data
downloaded from the PGC website). Unified quality control (QC) procedures,
Ricopilli pipeline, were used and genotype data were imputed using the 1KG
(Phase I Integrated Release Version 3). In each sample, associations were assessed
for imputed marker dosages by adjusting for PCs to control for population
stratification. After filtering on MAF ≥ 0.01, imputation quality score ≥0.6, about
9.5 million variants were used for a combined inverse-variance weighted fixed-
effect analysis.
To harmonize the GWAS summary statistics of breast cancer and
schizophrenia, we filtered the imputed markers by MAF ≥ 0.01, imputation quality
score ≥0.6 (R2 from MACH59 or INFO from IMPUTE60), removing duplicates,
insertion/deletion, and allele-mismatched variants. Six million seven hundred and
twenty-five thousand eight hundred and eighteen SNPs in autosome shared
between two GWAS were included for analysis.
In order to disentangle the potential confounding of genetic susceptibility to
lipid levels, we also utilized the GWAS summary statistics of TC, TG, and LDL
cholesterol as a negative control. We obtained the GWAS summary statistics of
blood lipids from the Global Lipids Genetics Consortium61, which included about
100,000 individuals with European ancestry (NTC= 100,184, NTG= 96,598, and
NLDL= 95,454) and 2.69 million SNPs. To be consistent, we only used SNPs that
were reported in GWASs of breast cancer and schizophrenia.
The individual-genotype data for schizophrenia was based on the S3 as part of
the Schizophrenia Working Group of PGC24. Cases of this study were adults with
two or more hospitalization due to schizophrenia or schizoaffective disorder,
ascertained through the Swedish Patient Register. Controls were randomly selected
from the Swedish population and had never been hospitalized for schizophrenia or
bipolar disorder. The data genotyped on different arrays were processed using the
PGC Ricopilli pipeline for QC and imputation24.
The register-based study was approved by the Central Ethical Review Board in
Stockholm, Sweden (Dnr 12–2013). The requirement of informed consent is
waived in register-based studies in Sweden. The S3 were approved by the Regional
Ethical Review Board in Stockholm, Sweden (Dnr 04/449/4), and informed consent
was obtained from every participant. Data from international consortia (summary
statistics) are publicly available.
Epidemiologic analyses. First, we examined schizophrenia-associated risk of
invasive breast cancer using a nested case–control design. Among 3,937,114
women, we excluded 39,990 women with breast cancer, 81,692 with other malig-
nancy, and 48,320 with emigration before January 1, 1990, or age 18 years,
whichever came later, and 982 with erroneous records. We followed the remaining
3,766,130 women until the diagnosis of any cancer, death, emigration, December
31, 2009, whichever came first. The average duration of follow-up was 15.2 years.
To assess the schizophrenia-associated risk of breast cancer, we first conducted
a nested case–control analysis, which preserves the validity of full prospective
cohort analysis22. Briefly, within this nationwide study base, we identified 94,626
women with newly diagnosed invasive breast cancer as cases. For each case, 30
women (whenever possible) who were free of cancer at the date of the case’s cancer
diagnosis (i.e., the reference date) were randomly selected from the study base. In
total, 2,838,765 controls were individually matched on year of birth and age at the
reference date. We then ascertained the date of a first-ever inpatient diagnosis of
schizophrenia before the reference date (since 1980). The median time from
schizophrenia to breast cancer diagnosis was 12.74 years. Both primary and
secondary diagnoses were used. To capture persons with schizophrenia who might
not have been hospitalized, we performed an additional analysis including
outpatient diagnoses of schizophrenia.
We derived ORs and 95% CIs from the conditional logistic regression by
comparing cases with controls. The estimates, however, should be interchangeably
interpreted as relative risk of breast cancer among patients with schizophrenia22.
The estimates were conditioned on the matching sets (i.e., inherently adjusted for
birth of year and age) and adjusted for educational levels (primary school, high
school, college and beyond, or unknown) and region of residence (southern,
central, or northern Sweden). To disentangle the environmental effect from
potential genetic factors, in a second model, we further adjusted for characteristics
shared between breast cancer and schizophrenia, including parity (0, 1–2, or ≥3),
pre-existing psychiatric disorder (yes or no; including all substance use disorders,
e.g., abuse of alcohol, tobacco, and drug etc.), and obesity (yes or no) at the
reference date.
Second, we assessed invasive breast cancer-associated risk of schizophrenia
using a matched cohort design. We prospectively followed these cases and controls
from the reference date until diagnosis of schizophrenia, cancer, death, emigration,
December 31, 2010, whichever came first. We excluded 548 cases and 11,399
controls with inpatient or outpatient diagnosis of schizophrenia before the
reference date. During the follow-up (i.e., from the reference date onward; median,
7.72 years), we further ascertained newly diagnosed schizophrenia in inpatient (and
outpatient) care. We calculated the hazard ratio of schizophrenia and 95% CI by
using the stratified Cox proportional hazards regression comparing cases and
controls. The approaches of adjustment in models were the same as the nested
case–control study.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18492-8 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4637 | https://doi.org/10.1038/s41467-020-18492-8 | www.nature.com/naturecommunications 7
In an additional analysis, we restricted the analysis to women of age at follow-up
during 18–44 years. Namely, we included women whose age at the reference date was
18–44 years for both analysis; in the analysis of breast cancer-associated schizophrenia
risk, we censored the follow-up when the individual turned age 45 years.
These analyses were conducted in STATA (version 14.2). All tests were two
sided and P < 0.05 indicated statistical significance.
PRS analyses. First, we tested the association between PRS for schizophrenia and
risk of breast cancer and vice versa, using the GWAS summary statistics from
breast cancer and schizophrenia. The SNPs reported in both GWAS were included
to generate the PRS using the software packages PRSice (version 1.25)62. LD
clumping (r2 < 0.1 in 500 kb window) used 1000 Genomes Project European
samples as LD reference (after removing MHC region). Similarly, subgroup ana-
lyses on ER-positive/negative breast cancer were also performed.
Second, to examine the association of breast cancer with schizophrenia in
women and men, we derived PRS for breast cancer for all participants in S3. The
harmonized GWAS summary statistics of breast cancer was considered as
discovery set for SNP selection and risk allele weighting. We further excluded
variants with MAF < 0.05, imputation quality score <0.8, or with ambiguous strand.
After LD clumping (r2 < 0.1 in 500 kb window) using the same LD reference as
above, 71,121 SNPs with relative independence remained for PRS calculation. We
generated PRS for breast cancer in the target sample as the sum of the imputed
SNP dosages weighted by the allele effect (logistic regression coefficients) from the
discovery set across all SNPs under a PT of 5 × 10−8, 1 × 10−6, 1 × 10−4, 1 × 10−3,
0.01, 0.05, 0.1, 0.2, 0.5, and 1, respectively. PLINK (version 1.9) was used for the
PRS profiling. All scores were standardized within each target set to account for
variation in SNP numbers used for PRS calculation. Subsequently, we examined the
associations using logistic regression in R (version 3.4.3). The variance explained by
PRS was calculated as the difference in variance from the full model including the
PRS and variance from the baseline model without PRS using Nagelkerke’s R-
squared63. We adjusted for first ten PCs and genotyping platform.
LD score genetic correlation analyses. We estimated the genetic correlation, i.e.,
the extent to which breast cancer and schizophrenia share genetic etiology, by using
LD score correlation64. This method requires only GWAS summary statistics and
the estimation is always controlled for sample overlap (if any). It is implemented in
the free open source LDSC (version 1.0.1) software package. Briefly, this method
quantifies the separate contributions of polygenic effects by examining the rela-
tionship between LD scores and test statistics of SNPs from GWAS summary
statistics and produces genetic correlation based on the deviation of chi-square
statistics from the null hypothesis. The genetic correlation was estimated by using
unconstrained-intercept LD score regression accounting for potential sample
overlap between GWASs of breast cancer and schizophrenia.
Identification of shared loci. To identify the most significant loci shared between
breast cancer and schizophrenia, we first plotted the associations of schizophrenia
lead SNPs (i.e., genome-wide significant markers after LD clumping based on r2 <
0.1 in 500 kb window) with breast cancer, by using the GWAS summary statistics
of both traits. A global test that approximates the average effects of a set of selected
SNPs on the other trait was carried out to highlight the overall effect of lead SNPs
for schizophrenia on breast cancer65. Moreover, the individual effect of lead SNPs
for schizophrenia on breast cancer was corrected for multiple comparison using the
false discovery rate method66. The remained significant SNPs, regardless of effect
direction, stand as potential regions shared with breast cancer. In addition, to assess
the effect of influential SNPs, we calculated the Cook’s distance for each SNP and
those with Cook’s distance >N/4 were removed. We further plotted the association
by removing SNPs iteratively until the heterogeneity test was no longer significant.
This procedure was done by using grs.filter.Qrs function in the gtx package in R.
Identical analyses were performed for breast cancer lead SNPs and their corre-
sponding associations with schizophrenia.
Next, we visualized the regional associations (500 kb on either side of the lead
SNPs that remained significant after correction for multiple comparison) with both
breast cancer and schizophrenia by integrating 1000 Genomes LD data with gene
annotation tracks using LocusZoom (version 1.4)67. As the signal at 19p13 shows
the similar pattern between both traits, we sought the known associations of lead
SNPs rs2965183 and rs2905426 in PhenoScanner database (http://www.
phenoscanner.medschl.cam.ac.uk/)27. Based on the established links of both SNPs
to lipids, we further plot the regional associations of locus 19p13 with TC, TG, and
LDL using the GWAS summary statistics. We also sought reported associations of
this region from GWAS Catalog (https://www.ebi.ac.uk/gwas/home) and calculated
R2 to rs2965183/rs2905426 in European population using LDmatrix (https://ldlink.
nci.nih.gov/?tab=ldmatrix).
Gene expression analyses. To capture potentially altered gene expression due to
lead SNPs rs2965183 and rs2905426, the eQTL analyses were then performed for
genes up to 1Mb on either side of each variant. Data on genetic variant and
expression in breast (N= 251), brain (N= 80–154 depending on brain regions), or
blood samples (N= 369) were used, through FUMA, from the GTEx Project29.
Cross-trait meta-analysis of GWAS summary statistics. To better capture the
genetic architecture shared by both traits, we performed cross-trait meta-analysis by
combining GWAS summary statistics for breast cancer and schizophrenia. We
applied metaUSAT (implemented in the R software package), a data-adaptive sta-
tistical approach for multivariate meta-analysis68. In brief, metaUSAT can be applied
to test the genetic associations of multiple traits by using only univariate summary
statistics (Z-score) from multiple studies. It provides an approximate asymptotic P
value for association and appropriately accounts for sample overlap between studies
by estimating the correlation matrix of summary statistics. To avoid detecting signals
unduly driven by association from one side, we only included SNPs with P value <5 ×
10−5 reported in both GWAS summary statistics for meta-analyses.
Functional mapping and annotation. We used FUMA69, a web-based platform
(http://fuma.ctglab.nl/), to perform functional mapping and annotation for the
shared genetic components associated with both breast cancer and schizophrenia.
To functionally annotate GWAS findings, FUMA uses information from 18 bio-
logical data repositories and tools to run two core processes. Based on the uploaded
results of cross-trait meta-analysis, 32 independent significant SNPs were identified
by FUMA (LD r2 < 0.6, Pmeta < 1 × 10−5), and 84 genes were mapped in either
positional (i.e., SNPs physically located inside a gene with up to 10 kb windows) or
eQTL mapping (based on breast, brain, or blood samples from the GTEx project as
described above). Pathways were then enriched from these genes using knowledge-
based databases, including Reactome, KEGG, GO Biological Process, and BioCarta.
The P values in eQTL and pathway analyses were corrected for multiple com-
parison using the false discovery rate method66.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The epidemiological analysis used Swedish registers are available from the Swedish
National Board of Health and Welfare (https://www.socialstyrelsen.se/en/statistics-and-
data/registers/) and the Statistics Sweden (https://www.statistikdatabasen.scb.se/pxweb/
en/ssd/). According to Swedish law, the authors are not able to make the dataset publicly
available. Data are, however, available for any researchers (including international
researchers) through formal applications to the aforementioned authorities. The primary
genetic analysis used publicly available GWAS summary statistics from the Breast Cancer
Association Consortium (available at http://bcac.ccge.medschl.cam.ac.uk/bcacdata/icogs-
complete-summary-results/) and Psychiatric Genomics Consortium (available at https://
www.med.unc.edu/pgc/download-results/). We also used reported genetic associations
from PhenoScanner database (http://www.phenoscanner.medschl.cam.ac.uk/) and
GWAS Catalog (https://www.ebi.ac.uk/gwas/home). Source data are provided with
this paper.
Code availability
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